Close

OncoGenex (OGXI) Gains; Phase 3 ENSPIRIT Trial to Continue Per Recommendation of IDMC

August 21, 2014 4:20 PM EDT Send to a Friend
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login